HHS Secretary Nominee Burwell Pledges To Promote Innovation At FDA
In an appearance before the Senate HELP committee, Sylvia Burwell addressed questions on accelerated drug approvals at FDA, the Independent Payment Advisory Board and metrics for enhancing development of new Medicare payment models.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
What's in – and what fell out of – the massive US stimulus package.